In 2014, strides were made in the care of haematological malignancies. In particular, the heterogeneity of multiple myeloma was unravelled, and new diagnostic criteria and frontline standards of care were proposed; new therapeutic approaches have been validated and approved in chronic lymphocytic leukaemia; and in chronic myeloid leukaemia, complete cytogenetic response was confirmed as the primary therapeutic end point.
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Lohr, J. G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91–101 (2014).
Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438–447 (2013).
Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 156, e538–e548 (2014).
Benboubker, L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl. J. Med. 371, 906–917 (2014).
Byrd, J. C. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 371, 213–223 (2014).
Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997–1007 (2014).
Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370, 1101–1110 (2014).
Hehlmann, R. et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J. Clin. Oncol. 32, 415–422 (2014).
Branford, S. et al. Prognosis for patients with CML and >10% BCR–ABL1 after 3 months of imatinib depends on the rate of BCR–ABL1 decline. Blood 124, 511–518 (2014).
Branford, S. et al. Any BCR–ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months [abstract]. Blood 122, a254 (2013).
J.F.S.-M. has acted in a consultancy or advisory capacity for Bristol–Myers Squibb, Celgene, Janssen, Millennium, MSD, Novartis and Onyx. H.M.K. has received research grants from Amgen, ARIAD, Bristol–Myers Squibb, Novartis and Pfizer.
About this article
Cite this article
San-Miguel, J., Kantarjian, H. Improved understanding of disease biology and treatment. Nat Rev Clin Oncol 12, 71–72 (2015). https://doi.org/10.1038/nrclinonc.2014.216